Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: An investigation of induction and time course: 2006 Innovations in Neuropsychopharmacology Award

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 1, 2008, Pages 54-63

  Yue, Jiang ^a   Miksys, Sharon ^a   Hoffmann, Ewa ^a   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Department of Pharmacology ^*  (Canada)

Author keywords

Animals; Brain; Central nervous system; Cytochrome P450 enzyme system; Metabolism; Nicotine; Parkinson disease; Smoking

Indexed keywords

BRAIN PROTEIN; CELL PROTEIN; CYTOCHROME P450 2D; LIVER PROTEIN; MESSENGER RNA; NEUROTOXIN; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN STEM; CONTROLLED STUDY; CORPUS STRIATUM; CYTOLYSIS; DRUG RESPONSE; ENZYME METABOLISM; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOBLOTTING; LIVER; LONG TERM CARE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RAT; SLOT BLOT HYBRIDIZATION; THALAMUS;

EID: 39149094615     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83-448.
2. Riddick DS, Lee C, Bhathena A, et al. Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metab Dispos 2004;32:367-75.
3. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004;36:243-77.
4. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
5. Miller GP, Hanna IH, Nishimura Y, et al. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Biochemistry 2001;40:14215-23.
6. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998;249:838-43.
7. Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003;13:173-81.
8. Yu AM, Idle JR, Herraiz T, et al. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 2003;13:307-19.
9. Yu AM, Idle JR, Krausz KW, et al. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 2003;305:315-22.
10. Hiroi T, Kishimoto W, Chow T, et al. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001;142:3901-8.
11. Kishimoto W, Hiroi T, Shiraishi M, et al. Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology 2004;145:699-705.
12. Gilham DE, Cairns W, Paine MJ, et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-25.
13. Suzuki T, Fujita S, Narimatsu S, et al. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4- tetrahydroisoquinoline in rat liver microsomes. FASEB J 1992;6:771-6.
14. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays 2002;24:308-18.
15. Chen ZR, Irvine RJ, Bochner F, et al. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci 1990;46:1067-74.
16. Jolivalt C, Minn A, Vincent-Viry M, et al. Dextromethorphan O-demethylase activity in rat brain microsomes. Neurosci Lett 1995;187:65-8.
17. Tyndale RF, Li Y, Li NY, et al. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos 1999;27:924-30.
18. Lin LY, Kumagai Y, Cho AK. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem Res Toxicol 1992;5:401-6.
19. Miksys S, Rao Y, Hoffmann E, et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002;82:1376-87.
20. Chinta SJ, Pai HV, Upadhya SC, et al. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res Mol Brain Res 2002;103:49-61.
21. Siegle I, Fritz P, Eckhardt K, et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001;11:237-45.
22. McFayden MC, Melvin WT, Murray GI. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol 1998;55:825-30.
23. Tyndale RF, Sunahara R, Inaba T, et al. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-8.
24. Voirol P, Jonzier-Perey M, Porchet F, et al. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000; 855:235-43.
25. Britto MR, Wedlund PJ. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab Dispos 1992;20:446-50.
26. Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 2004;36:313-33.
27. Funck-Brentano C, Boelle PY, Verstuyft C, et al. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005;61:821-9.
28. Anandatheerthavarada HK, Williams JF, Wecker L. The chronic administration of nicotine induces cytochrome P450 in rat brain. J Neurochem 1993;60:1941-4.
29. Miksys S, Hoffmann E, Tyndale RF. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 2000;59:1501-11.
30. Anandatheerthavarada HK, Williams JF, Wecker L. Differential effect of chronic nicotine administration on brain cytochrome P4501A1/2 and P4502E1. Biochem Biophys Res Commun 1993;194: 312-8.
31. Howard LA, Miksys S, Hoffmann E, et al. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003;138:1376-86.
32. Joshi M, Tyndale RF. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metab Dispos 2006;34: 647-52.
33. Miksys S, Rao Y, Sellers EM, et al. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 2000;30:547-64.
34. Howard LA, Micu AL, Sellers EM, et al. Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J Pharmacol Exp Ther 2001;299:542-50.
35. Cribb A, Nuss C, Wang R. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab Dispos 1995;23:671-5.
36. Guslandi M. Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study. Int J Colorectal Dis 1999;14:261-2.
37. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl) 1999;143:158-65.
38. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000;113:117-20.
39. Kelton MC, Kahn HJ, Conrath CL, et al. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43:274-82.
40. Micu AL, Miksys S, Sellers EM, et al. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J Pharmacol Exp Ther 2003;306:941-7.
41. Benowitz NL. Nicotine addiction. Prim Care 1999;26:611-31.
42. Ghosheh O, Dwoskin LP, Li WK, et al. Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2′-(14)C]nicotine. Drug Metab Dispos 1999;27:1448-55.
43. Hwa Jung B, Chul Chung B, Chung SJ, et al. Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. J Control Release 2001;77:183-90.
44. Kawashima H, Sequeira DJ, Nelson DR, et al. Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing Imipramine N-demethylation. J Biol Chem 1996;271:28176-80.
45. Schulz-Utermoehl T, Bennett AJ, Ellis SW, et al. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 1999;9:357-66.
46. Hedlund E, Wyss A, Kainu T, et al. Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene. Mol Pharmacol 1996;50:342-50.
47. Warner M, Gustafsson JA. Effect of ethanol on cytochrome P450 in the rat brain. Proc Natl Acad Sci U S A 1994;91:1019-23.
48. Mizuno D, Hiroi T, Ng P, et al. Regulation of CYP2D expression in rat brain by toluene. Osaka City Med J 2003;49:49-56.